European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

New Medicines for Trypanosomatidic Infections

Objectif

The infectious diseases burden imposed by the parasites of Trypanosomatidae family represents a huge problem on people’s lives in countries where these diseases are endemic. Problems associated with existing drugs include inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. New drugs are urgently needed now and in the foreseeable future. The New Medicine for Trypanosomatid Infections (NMTrypI) consortium uses a highly interdisciplinary approach to optimize pteridine, benzothiazole and miltefosine derivatives, as well as natural products against Trypanosomatids. The lead compounds target mechanisms that are associated with protozoa virulence and pathogenicity. The major objectives of this 3-year project are: i) development of drug leads which may be used in combination with a known or an investigational drugs, by using a common drug discovery platform established by experts in their respective fields, ii) development of pharmacodynamic biomarkers enabling the proteomic profiling of compound efficacy and early identification of drug resistance. NMTrypI addresses sleeping sickness, leishmaniasis, and Chagas disease. The partners are SMEs (5) and academics (8) in Europe and in disease-endemic countries (Italy, Greece, Portugal, Sudan, and Brazil). The new platform enables high throughput screening of compound libraries, lead development, testing in relevant animal models, as well as toxicology and safety testing. NMTrypI will translate drug leads into drug candidacy through 6 scientific work packages (WPs1-6) supported by two transversal WPs dedicated to project dissemination and management. The major strength of the consortium lies in the complementary partners’expertise and the integrated platform that will provide:
- at least 1-2 innovative, less toxic and safer drug candidates for Trypanosomatid infections compared to existing ones,
- early phase biomarkers for efficacy prediction (overall improved efficacy and safety)

Champ scientifique

Programme(s)

Thème(s)

Appel à propositions

FP7-HEALTH-2013-INNOVATION-1
Voir d’autres projets de cet appel

Régime de financement

CP-FP - Small or medium-scale focused research project

Coordinateur

UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA
Contribution de l’UE
€ 889 824,31
Adresse
VIA UNIVERSITA 4
41121 Modena
Italie

Voir sur la carte
Région
Nord-Est Emilia-Romagna Modena
Type d’activité
Higher or Secondary Education Establishments
Contact administratif
Maria Paola Costi (Prof.)
Liens
Coût total
Aucune donnée

Participants (13)

Partager cette page

Télécharger

Dernière mise à jour: 30 Mars 2022

Mon livret

Permalink: https://cordis.europa.eu/project/id/603240/fr

European Union, 2024